Eculizumab Intravenous Route

How is Eculizumab Intravenous Route dosed?

The dosage for Eculizumab Intravenous Route depends on the specific condition being treated:

1. Paroxysmal Nocturnal Hemoglobinuria (PNH): Dosage varies based on body weight and is typically given every two or four weeks.
2. Atypical Hemolytic Uremic Syndrome (aHUS): Dosage is determined by the treating physician and is usually administered every two or four weeks.
3. Generalized Myasthenia Gravis (gMG): The dosage is 900 mg administered as an intravenous infusion every four weeks.
4. Neuromyelitis Optica Spectrum Disorder (NMOSD): The dosage is 900 mg administered as an intravenous infusion every eight weeks. Please consult with a healthcare professional for the appropriate dosage and frequency for your specific situation.

What is the dosage form of Eculizumab Intravenous Route?

The dosage form of Eculizumab Intravenous Route is a solution.

How is Eculizumab Intravenous Route administered?

Eculizumab Intravenous Route is administered through a needle placed into one of the veins. It must be injected slowly, so the IV tube will need to stay in place for at least 35 minutes in adults and 1 to 4 hours in children. A nurse or other trained health professional will be responsible for providing the medicine.

What are common precautions when taking Eculizumab Intravenous Route?

Common precautions when taking Eculizumab Intravenous Route include:

1. Infection: Eculizumab may decrease your body's ability to fight infections. Avoid contact with people who are sick or have infections.
2. Meningococcal Infection: Eculizumab should not be given to patients with meningococcal infection.
3. Lack of Current Vaccination Against Meningitis: Eculizumab should not be given to patients without current vaccination against meningitis unless urgent treatment is needed.
4. Neutropenia or Weak Immune System: Use with caution in individuals with neutropenia or a weak immune system, as it may cause side effects to become worse and increase the risk of infection.
5. Proper Usage: Eculizumab must be administered by a nurse or other trained health professional through a needle placed into a vein. The injection should be slow, and the IV tube must remain in place for at least 35 minutes in adults and 1 to 4 hours in children.
6. Monitoring for Side Effects: Be aware of potential side effects, such as headaches, nausea, vomiting, fever, stiff neck or back, rash, confusion, muscle aches, or sensitivity to light. Report these symptoms to your healthcare professional immediately.
7. Meningococcal Vaccination: Receive the meningococcal vaccine at least 2 weeks before starting Eculizumab treatment. You may also be given antibiotic medications for 2 weeks to prevent infections if you need to start Eculizumab right away. Consult your doctor to determine if you need another dose of the vaccine.
8. Patient Safety Card: Obtain a patient safety card that lists the symptoms of meningococcal infections and instructions on what to do if you experience them. Carry the card with you at all times during treatment and for 3 months after your last dose, and show it to any doctor who treats you. Follow your healthcare professional's instructions and inform them of any other medical conditions or medications you are taking to ensure safe and effective use of Eculizumab.